ADVERTISEMENT

Mankind Pharma Q1 Results Review - Margins Impacted By One-Offs: Systematix

The acquisition of Bharat Serums and Vaccines shall become EPS accretive from the second year, says the brokerage.

<div class="paragraphs"><p>Mankind Pharma Ltd.'s R&amp;D facility. (Source: company website)</p></div>
Mankind Pharma Ltd.'s R&D facility. (Source: company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit